To evaluate the safety and tolerability of ALX148 in combination with enfortumab vedotin in subjects with previously treated locally advanced or metastatic urothelial carcinoma. To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of ALX148 in combination with enfortumab vedotin.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina
Matthew Milowsky
Medicine- Oncology
Clinical or Medical
Interventional
Cancer (Other Cancers)
Urinary and Bladder
22-2399
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
